• Francesco Bandello, Umberto De Benedetto, Karl Anders Knutsson, Maurizio Battaglia Parodi, Maria Lucia Cascavilla, and Pierluigi Iacono.
• Department of Ophthalmology, University Vita-salute, Scientific Institute San Raffaele, Milan, Italy.
• Clin Ophthalmol. 2011 Jan 1; 5: 1303-8.

AbstractDiabetic macular edema is the major cause of visual acuity impairment in diabetic patients. The exact etiopathogenesis is unknown and, currently, grid/focal retinal laser photocoagulation represents the recommended treatment. It has been demonstrated that vascular endothelial growth factor (VEGF) plays a key role in the pathogenesis of diabetic macular edema by mediating vascular permeability and accumulation of intracellular and extracellular fluid, and thereby represents an appealing candidate as a therapeutic target for the treatment of diabetic macular edema. The advent of intravitreal anti-VEGF drugs has opened up a new era for the management of diabetic macular edema. At present, three anti-VEGF substances are available for routine clinical use, ie, pegaptanib, ranibizumab, and bevacizumab. The aim of this review is to summarize the evidence supporting the use of ranibizumab in clinical practice. Most of the studies analyzed in this review are prospective, controlled clinical trials that have focused on documenting the therapeutic effect of ranibizumab and its safety, providing encouraging results.

3 keywords...

hide…